De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Vera Therapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO Vera Therapeutics' is Marshall Fordyce, benoemd in May2016, heeft een ambtstermijn van 8.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.43M, bestaande uit 17.1% salaris en 82.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.42% van de aandelen van het bedrijf, ter waarde $ 10.13M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 4 jaar.

Belangrijke informatie

Marshall Fordyce

Algemeen directeur

US$3.4m

Totale compensatie

Percentage CEO-salaris	17.1%
Dienstverband CEO	8.4yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

Analyse CEO-vergoeding

Hoe is Marshall Fordyce's beloning veranderd ten opzichte van Vera Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$108m
Mar 31 2024	n/a	n/a	-US$94m
Dec 31 2023	US$3m	US$586k	-US$96m
Sep 30 2023	n/a	n/a	-US$103m
Jun 30 2023	n/a	n/a	-US$107m
Mar 31 2023	n/a	n/a	-US$102m
Dec 31 2022	US$4m	US$551k	-US$89m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$56m
Mar 31 2022	n/a	n/a	-US$45m
Dec 31 2021	US$1m	US$479k	-US$33m
Sep 30 2021	n/a	n/a	-US$59m
Jun 30 2021	n/a	n/a	-US$55m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$3m	US$360k	-US$53m

Compensatie versus markt: De totale vergoeding ($USD 3.43M ) Marshall } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).

Compensatie versus inkomsten: De vergoeding van Marshall is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Marshall Fordyce (49 yo)

8.4yrs

Tenure

US$3,429,733

Compensatie

Dr. Marshall W. Fordyce, M.D. is Founder of Vera Therapeutics, Inc. and has been its President, Chief Executive Officer and Director since May 2016. From April 2011 to July 2016, Dr. Fordyce held a number...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Marshall Fordyce	Founder	8.4yrs	US$3.43m	0.42% $ 9.3m
Sean Grant	Chief Financial Officer	3.3yrs	US$1.76m	0.041% $ 914.6k
David Johnson	Chief Opearating Officer	less than a year	geen gegevens	geen gegevens
Joseph Young	Senior VP of Finance & Chief Accounting Officer	3.4yrs	geen gegevens	0.035% $ 782.8k
Julien Capers	Senior Vice President of Legal	2.8yrs	geen gegevens	geen gegevens
Kelly Rauber	Senior Vice President of Human Resources	2.8yrs	geen gegevens	geen gegevens
Tom Doan	Senior Vice President of Development Operations	4.6yrs	geen gegevens	geen gegevens
Lauren Frenz	Chief Business Officer	7.2yrs	geen gegevens	geen gegevens
Neeraj Pakala	Senior VP and Head of Product Development & Manufacturing	1.8yrs	geen gegevens	geen gegevens
Kerry Cooper	Senior Vice President of Medical Affairs	1.4yrs	geen gegevens	geen gegevens
Robert Brenner	Chief Medical Officer	less than a year	geen gegevens	geen gegevens
William Turner	Chief Development Officer	less than a year	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VERA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Marshall Fordyce	Founder	8.4yrs	US$3.43m	0.42% $ 9.3m
Maha Katabi	Independent Director	4yrs	US$153.63k	0% $ 0
Michael Morrissey	Independent Chairman of the Board	2.4yrs	US$187.13k	0% $ 0
Patrick Gerald Enright	Independent Director	4yrs	US$155.63k	0% $ 0
Beth Seidenberg	Independent Director	8.3yrs	US$153.13k	0.27% $ 6.1m
Scott William Morrison	Independent Director	4.5yrs	US$160.63k	0% $ 0
Andrew Cheng	Independent Director	7.4yrs	US$154.63k	0.032% $ 708.2k
Christy Oliger	Director	less than a year	geen gegevens	0.0054% $ 121.0k
Kimball Hall	Independent Director	2.8yrs	US$152.04k	0% $ 0

4.0yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VERA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Vera Therapeutics Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Recent updates

Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Vera Therapeutics, Inc. Announces Expanded Atacicept Development Program in Multiple Autoimmune Kidney Diseases

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics, Inc.(NasdaqGM:VERA) dropped from Russell 3000E Value Index

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Vera Therapeutics, Inc., Annual General Meeting, May 15, 2024

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 36% to US$32.11

New minor risk - Share price stability

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy

Vera Therapeutics, Inc. Announces Executive Changes

New minor risk - Share price stability

Price target increased by 12% to US$22.14

New major risk - Revenue and earnings growth

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

New minor risk - Share price stability

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Price target decreased by 18% to US$15.67

Chief Financial Officer recently bought US$100k worth of stock

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy (Igan)

Price target decreased to US$19.17

Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Chief Development Officer exercised options and sold US$148k worth of stock

Founder exercised options to buy US$1.1m worth of stock.

High number of new directors

Chief Development Officer exercised options and sold US$95k worth of stock

Founder exercised options and sold US$576k worth of stock

Chief Development Officer exercised options and sold US$186k worth of stock

Founder exercised options and sold US$622k worth of stock

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Founder exercised options and sold US$354k worth of stock

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Vera Therapeutics Completes Patient Enrollment in Phase 2B Origin Clinical Trial of Atacicept for the Treatment of Iga Nephropathy

Chief Financial Officer recently bought US$68k worth of stock

Vera Therapeutics, Inc. Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

High number of new directors

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

High number of new directors

Vera Therapeutics, Inc., Annual General Meeting, May 24, 2022

Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

High number of new directors

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Vera Therapeutics soars 16% on three new favorable view from analysts

Independent Chairman of the Board recently bought US$215k worth of stock

Vera Therapeutics, Inc. has completed an IPO in the amount of $47.85 million.

Analyse CEO-vergoeding

CEO

Tenure